Details of the Drug

General Information of Drug (ID: DMB4HCT)

Drug Name

Sparfloxacin

Synonyms

Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

392.4

Topological Polar Surface Area (xlogp)

0.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability: 92% of drug becomes completely available to its intended biological destination(s) [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.7 mL/min/kg [4]
Elimination: 10% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.486 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.55% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 1.1 mg/mL [2]

Chemical Identifiers

Formula: C19H22F2N4O3
IUPAC Name: 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
Canonical SMILES: C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
InChI: InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
InChIKey: DZZWHBIBMUVIIW-DTORHVGOSA-N

Cross-matching ID

PubChem CID: 60464
ChEBI ID: CHEBI:9212
CAS Number: 110871-86-8
DrugBank ID: DB01208
TTD ID: D0K6GZ
VARIDT ID: DR00791
ACDINA ID: D01439

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Modulator	[7]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sparfloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[22]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[22]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Oliceridine.	Acute pain [MG31]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Ivabradine.	Angina pectoris [BA40]	[23]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Dronedarone.	Angina pectoris [BA40]	[24]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[22]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Posaconazole.	Aspergillosis [1F20]	[22]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Sparfloxacin and Pirbuterol.	Asthma [CA23]	[25]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[22]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Retigabine.	Behcet disease [4A62]	[21]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[22]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[22]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[26]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[21]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Sparfloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Sparfloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[22]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Osilodrostat.	Cushing syndrome [5A70]	[21]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Clomipramine.	Depression [6A70-6A7Z]	[22]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[22]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[22]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Ingrezza.	Dystonic disorder [8A02]	[22]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Solifenacin.	Functional bladder disorder [GC50]	[22]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[22]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Sparfloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[28]
Iron	DMAP8MV	Moderate	Decreased absorption of Sparfloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[29]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[30]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Crizotinib.	Lung cancer [2C25]	[22]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Ceritinib.	Lung cancer [2C25]	[22]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[26]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Osimertinib.	Lung cancer [2C25]	[22]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Selpercatinib.	Lung cancer [2C25]	[21]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lumefantrine.	Malaria [1F40-1F45]	[21]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[22]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[22]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and LGX818.	Melanoma [2C30]	[22]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Panobinostat.	Multiple myeloma [2A83]	[22]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Fingolimod.	Multiple sclerosis [8A40]	[24]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Ozanimod.	Multiple sclerosis [8A40]	[22]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Romidepsin.	Mycosis fungoides [2B01]	[21]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[22]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[22]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[21]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lofexidine.	Opioid use disorder [6C43]	[22]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Rucaparib.	Ovarian cancer [2C73]	[22]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[21]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Pimavanserin.	Parkinsonism [8A00]	[22]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[31]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lefamulin.	Pneumonia [CA40]	[21]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Sparfloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[32]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Degarelix.	Prostate cancer [2C82]	[22]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and ABIRATERONE.	Prostate cancer [2C82]	[22]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Enzalutamide.	Prostate cancer [2C82]	[22]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Sparfloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[33]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Sparfloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[34]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Quetiapine.	Schizophrenia [6A20]	[22]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Sparfloxacin and Aripiprazole.	Schizophrenia [6A20]	[35]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Iloperidone.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Paliperidone.	Schizophrenia [6A20]	[22]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Amisulpride.	Schizophrenia [6A20]	[22]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Asenapine.	Schizophrenia [6A20]	[22]
Docetaxel	DMDI269	Minor	Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[26]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[22]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Taxol	DMUOT9V	Minor	Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[26]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Pitolisant.	Somnolence [MG42]	[22]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Lenvatinib.	Thyroid cancer [2D10]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Sparfloxacin and Cabozantinib.	Thyroid cancer [2D10]	[22]
-----------


⏷ Show the Full List of 79 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Magnesium stearate	E00208	11177	lubricant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Hydroxyethyl cellulose	E00700	Not Available	Coating agent; Suspending agent; Binding agent; Viscosity-controlling agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sparfloxacin 200mg tablet	200mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020677.
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
11	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
13	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
14	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
15	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
16	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
17	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
19	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
20	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
21	Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
22	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Canadian Pharmacists Association.
25	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
26	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
27	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
28	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
29	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
30	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
31	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
32	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
33	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
34	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
35	Cerner Multum, Inc. "Australian Product Information.".